MedTrace Logo

Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients

NCT02555787 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4430

Last updated 2024-10-31

No results posted yet for this study

Summary

A study to evaluate changes over time in renal function from baseline (time of conversion) up until five years post conversion in kidney transplant patients converted from tacrolimus twice daily (BD) formulations to a once daily formulation as Advagraf.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Tacrolimus

oral

Sponsors & Collaborators

  • Astellas Pharma Europe Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Affairs Europe · Astellas Pharma Europe Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-05
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Australia
  • Austria
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Italy
  • Japan
  • Malaysia
  • Netherlands
  • Philippines
  • Poland
  • Portugal
  • Romania
  • Serbia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02555787 on ClinicalTrials.gov